Fund Description
The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®. The fund invests in securities and derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times (2x) the daily return of the index. The index is a modified capitalization weighted index that includes securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark ("ICB") which also meet other eligibility criteria determined by NASDAQ. The fund is non-diversified.
Fund Snapshot Updated 05.22.2013
| Previous Close | $99.07 | Expense Ratio | 0.95% |
| YTD Return | 71.2% | Avg. 30-Day Volume | 63,097 |
| 1-Year Return | 108.1% | Market Cap | Loading... |
| Bid | $98.95 | Shares Outstanding | 1,150,000 |
| Ask | $99.31 | Dividends | $0.00 |
| Top 10 Holdings | |
|---|---|
| Regeneron Pharmaceuticals (REGN) | 10.76% |
| Gilead Sciences Inc (GILD) | 8.62% |
| Amgen Inc (AMGN) | 7.18% |
| Celgene Corp (CELG) | 6.59% |
| Biogen Idec Inc (BIIB) | 6.20% |
| Alexion Pharmaceuticals Inc (ALXN) | 5.98% |
| Vertex Pharmaceuticals Inc (VRTX) | 4.76% |
| Biomarin Pharmaceutical Inc (BMRN) | 3.23% |
| Perrigo Co (PRGO) | 3.17% |
| Onyx Pharmaceuticals Inc (ONXX) | 2.69% |
| % of Total Holdings | 59.20% |
